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Topical ophthalmic delivery of active ingredients can be achieved using cationic nanoemulsions. In the last decade, Novagali
Pharma has successfully developed and marketed Novasorb, an advanced pharmaceutical technology for the treatment of
ophthalmic diseases. This paper describes the main steps in the development of cationic nanoemulsions from formulation to
evaluationinclinicaltrials.Amajorchallengeoftheformulationworkwastheselectionofacationicagentwithanacceptablesafety
proﬁle that would ensure a suﬃcient ocular surface retention time. Then, toxicity and pharmacokinetic studies were performed
showing that the cationic emulsions were safe and well tolerated. Even in the absence of an active ingredient, cationic emulsions
were observed in preclinical studies to have an inherent beneﬁt on the ocular surface. Moreover, clinical trials demonstrated the
eﬃcacy and safety of cationic emulsions loaded with cyclosporine A in patients with dry eye disease. Ongoing studies evaluating
latanoprost emulsion in patients with ocular surface disease and glaucoma suggest that the beneﬁcial eﬀects on reducing ocular
surface damage may also extend to this patient population. The culmination of these eﬀorts has been the marketing of Cationorm,
a preservative-free cationic emulsion indicated for the symptomatic treatment of dry eye.
1.Introduction
Ophthalmic diseases are most commonly treated by topical
eye-drop instillation of aqueous products. These formu-
lations, however, raise technical problems (e.g., solubility,
stability, and preservation) and clinical issues (eﬃcacy, local
toxicity and compliance). Conventional aqueous solutions
are limited to water-soluble molecules and by the fact
that within two minutes after instillation over 80% of the
product is eliminated via the nasolacrimal drainage system
limiting ocular penetration of the drug to less than 1%
of the administered dose [1]. Consequently, pharmaceutical
companieshavebeenfacedwiththechallengeofdevelopinga
formulation for topical administration which would expand
the range of potential active ingredients, remain longer
on the ocular surface, and provide sustained therapeutic
concentrations in addition to meeting the regulatory criteria
forapproval.Themainchallengesinoculardrugdeliveryand
key considerations to develop an ophthalmic preparation are
listed in Table 1.
Nanotechnologies are currently considered the best solu-
tion to improving the ocular delivery of ophthalmic drugs
even though products reaching the market using nanotech-
nologies are still rare [2]. Some reasons for this are that most
of the nanosystems, even the pharmaceutically eﬃcient ones,
haveencounteredtechnicalissuessuchasstabilityofcolloidal
systems [3], requirement for new excipients or use of organic
solvents noncompliant to regulatory standards, unknown or
unacceptable toxicity proﬁles [4], or unique scale-up and
manufacturing requirements.
Notwithstanding, nanotechnology remains a promising
approach for ophthalmic drug delivery. Compared to cur-
rently available approaches for administering eye drops,
nanosystems with bioadhesive properties (e.g., cationic
nanoemulsions) are more eﬃcient at delivering the appro-
priate concentrations of bioactive molecules to the eye. The2 Journal of Drug Delivery
Table 1: The main challenges in ocular drug delivery and key
considerations.
Challenges
Absorption: only 3 to 4% ocular bioavailability after topical
administration with traditional eye drops
Poorly-soluble drugs: conventional aqueous eye drops not suitable
for lipophilic drugs (40–60% of new chemical entities)
Patient compliance: multiple instillations are often needed with
eye drops to reach therapeutic levels
High tolerability/comfort requirements limit the formulation
options
Excipient choice: few excipients listed in ophthalmology (oils,
surfactants, polymers...)
Posterior segment drug delivery: no topical system for the posterior
segment; invasive treatments are used due to lack of alternatives
Considerations
Anatomy & physiology of the eye: mucus layer, eyelids,
metabolism, blink wash-out...
Tear composition: lipid outer layer, stability of the tear ﬁlm,
enzymes...
Disease state: impact of keratitis or inﬂammation on absorption
and clearance...
Ocular comfort: tolerability of the formulation, pH, osmolality,
viscosity, drop size...
Patient expectations: type of packaging and squeeze ability
impacting compliance...
Drug loading: impact on absorption, eﬃcacy, dosing regimen,
compliance...
mechanism underlying the bioadhesiveness of nanosystems
is an electrostatic interaction which prolongs the residence
timeontheocularsurface[5].Tocreateanelectrostaticinter-
action with the negatively charged cells of the ocular surface,
the vector should be positively charged. This is the advantage
of the Novasorb cationic nanoemulsion technology.
The aim of this article is to describe the development
of the cationic nanoemulsion technology from bench to
patients. The ﬁrst stage of development after an initial proof-
of-concept carried out at the University of Jerusalem was to
formulate the nanoemulsion with a cationic agent, an oily
phase and surfactants compliant with international phar-
macopeias (i.e., US and EU pharmacopeias). The objective
was to provide a stable and sterile cationic nanoemulsion
loadedwithanactiveingredientapprovablebytheregulatory
agencies. The completion of a full preclinical package and
clinical trials in patients with ocular surface disease has led
to the successful launch of the ﬁrst product based on the
cationic nanoemulsion technology.
2. Cationic Nanoemulsion for Ocular Delivery
As the neuroretina is an extension of the central nervous
system, the external eye and its adnexa are designed to
protect the internal ocular structures, particularly from
harmful chemicals [6]. The ﬁrst ocular barrier is the eyelid
which acts as a shutter preventing foreign substances from
contact with the ocular surface. The second barrier is the
tears which are continuously secreted to wash the ocular
surface of exogenous substances. Hence, the tears are mainly
responsible for the short residence time and low absorption
of drugs applied topically to the eye. The last protective
ocular barrier is the cornea. The neuronal system of the
cornea is able to detect changes in pH and osmolality which
caninducereﬂexblinkingandtearing.Also,thecorneaforms
a tight structural barrier made of three diﬀerent tissue layers
with alternating hydrophilic and lipophilic properties to
prevent the intraocular absorption of unwanted substances
[7].
Many attempts have been made to prolong the exposure
time of topically applied ocular treatments and to improve
their bioavailability, therapeutic eﬃcacy, or patient compli-
ance by reducing the number of required administrations
[8–10]. Hydrogels, now widely used in the ophthalmic
pharmaceutical industry, have enabled, for example, a
decrease in the frequency of timolol administrations from
two instillations daily to only one. Several excipients with
either viscosifying or bioadhesive properties are commonly
used (carbopol gels, cellulose derivatives, dextran, gelatin
glycerin, polyethylene glycol, poloxamer 407, polysorbate 80,
propylene glycol, polyvinyl alcohol, polyvinyl pyrrolidone)
to prolong the ocular residence time. The use of such
excipients, however, remains applicable to only hydrophilic
drugs and the advantage of increasing the viscosity must
be balanced against the potential disadvantage of inducing
ocular disturbances due to the blurring of vision as a
result of a change in the refractive index on the ocular
surface.Furthermore,otherdisadvantagesofhigherviscosity
are that more viscous solutions do not easily exit from
the bottle tip and may impose limits to the sterilization
options during manufacturing. Most recently, sophisticated
approaches like punctal plugs with active ingredient [11],
contact lens-releasing glaucoma medications, and injectable
biodegradable micro- and nanoparticles were proposed but
are today at too early a stage to be available to patients [8].
In addition to the challenges of increasing exposure,
numerous lipophilic and poorly water-soluble drugs have
become available in recent years that could be applicable
to the treatment of a variety of ocular conditions. These
drugs represent a formulation challenge for pharmaceutical
scientists because of aqueous solubility limitations. Dosage
forms for topical ocular application of lipophilic drugs
include oily solutions, micellar solutions, lotions, ointments,
and suspensions. The ocular administration of such dosage
forms is not only uncomfortable for the patient but also
of limited eﬃcacy. Despite a large variety of submicron-
sized colloidal carriers in the ophthalmic drug delivery ﬁeld,
nanoparticles and liposomes attract most of the attention
since they appear to have the potential to yield greater
eﬃcacy over existing formulations [12, 13].
In the last decade, oil-in-water-type lipid emulsions,
primarily intended for parenteral applications, have been
investigated and are now being exploited as a vehicle to
improve the ocular bioavailability of lipophilic drugs [14,
15]. Among these, nanoemulsions are considered excellent
alternative formulations to deliver lipophilic drug substancesJournal of Drug Delivery 3
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Figure 1:Cationicnanoemulsioninteractingwithnegatively chargedcornealcells.Theeﬀectsofthecationicemulsionare(1)tobringlipids
to stabilize the tear ﬁlm, (2) to interact electrostatically with mucins, and (3) to improve ocular absorption.
to the eye. Emulsions provide a high encapsulation rate, an
enhanced stability of the active ingredient, and enhanced
ocular penetration. The ﬁrst marketed ophthalmic emulsion
drug product was Restasis (Allergan), a preservative-free
anionicemulsionofcyclosporineA(CsA)at0.05%indicated
toincreasetearproductioninpatientswhosetearproduction
is presumed to be suppressed due to ocular inﬂammation.
Although approved by FDA in 2002, Restasis was never
accepted by European authorities. Other emulsion-based eye
drops available on the US market are artiﬁcial tears (Soothe
(Bausch & Lomb) and Refresh Endura (Allergan)). Other
ophthalmic nanoemulsions are under development and
among them are the products resulting from the Novasorb
technology, originated from work at the Hebrew University
ofJerusalembyProfessorSimonBenitaanddevelopedbythe
French pharmaceutical company Novagali Pharma.
The Novasorb technology platform is based on the
cationic nanoemulsion approach. The overall Novasorb
strategy exploits the fact that the corneal and conjunctival
cells and the mucus layer of glycosyl amino glycans lining
the ocular surface are negatively charged at a physiological
pH [16]. When applying a positively charged formulation to
the eye it is likely that an electrostatic attraction will occur
prolonging the residence time of the formulation on the
ocular surface (Figure 1). In addition, the nanosize of the
oil droplets creates a huge contact surface with the ocular
surface cells enabling enhanced absorption. This approach
was primarily conceived for oral administration [17] and it
wasadapted afewyearslatertooculardeliverybyKlangetal.
[18] to deliver indomethacin and Abdulrazik and coworkers
[19] who intended to deliver cyclosporine A.
The potential of cationic emulsions for ophthalmic drug
deliverywasrapidlyseentooﬀeradvantagesovertheexisting
topical drug delivery vehicles [20–22]. However, this drug
delivery approach was not exempt of hurdles and technology
challenges particularly in the formulation phase as we will
see further. During the development (from nonclinical to
clinical),theproductshadtogobacktotheformulationstage
to optimize their physicochemical properties due to stability,
toxicity, or pharmacokinetic issues. Up to three generations
of cationic nanoemulsions were then tested and patented
over the 10 years of development [23–25].
3. Formulation Development
3.1. Cationic Agent. The surface charge of the nanoemulsion
is deﬁned by the zeta potential. It corresponds to the electric
potential surrounding the oil nanodroplet at the plane
of hydrodynamic shear. It is measured by electrophoretic
mobility. The latter depends on the nature of the cationic
agent, its concentration and the electrolyte environment of
the oil nanodroplets. In addition to increasing the residence
time on the negatively charged ocular surface, the positive
chargeofthecationicagentcontributestothestabilizationof
the emulsion by creating an electrostatic repulsion between
the oil droplets of the nanoemulsion [26]. Evidence that the
speciﬁc nature of the cationic molecule may be responsible
for improved uptake properties was supplied by Calvo
et al. who showed that two diﬀerent types of cationic
indomethacin loaded nanocapsules (coated with poly-L-
lysine or chitosan) resulted in completely diﬀerent drug
kinetics proﬁles [27]. Therefore, the cationic agent selected
needstobecarefullyconsideredpriortostartingpharmaceu-
tical development as the success of the formulation is highly
dependent upon the choice of the cationic agent as will be
discussed further.
Novagali showed that below a zeta potential of +10mV,
nanoemulsions could not be autoclaved without destabiliz-
ing the oil droplets. Therefore, the ﬁrst challenge of the
Novasorb technology was to make a cationic emulsion with a
zeta potential suﬃciently high to stabilize the nanoemulsion,
yetwithacationicsurfactantconcentrationaslowaspossible
to avoid compromising the safety of the nanoemulsion. The
optimal range for the zeta potential was demonstrated to
be between +20mV and +40mV. Review of the literature
revealed that of the numerous cationic agents described
(Table 2) most of them are surfactants, indeed the positively
charged region of the molecule does not enter the oil core
of the droplet but instead remains at the surface, rendering
them very useful for emulsions. Unfortunately, very few are
listed in pharmacopeias or accepted for ophthalmic products
due to stability or toxicity issues.
Compared to anionic and nonionic surfactants, cationic
surfactants are known to be the most toxic surfactants [28].
Therefore, in order to develop the Novasorb technology
it was necessary to ﬁnd an appropriate cationic surfactant4 Journal of Drug Delivery
Table 2: Chemical structures of common molecules used as cationic agent in drug delivery.
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which would provide a suﬃciently high cationic charge, have
a low toxicity, and conform to regulatory standards.
Stearylamine is one of the most widely used cationic
lipidsintheacademicworldespeciallyforthemanufactureof
cationicliposomes[29]orcationicemulsions [19].However,
since this primary amine is very reactive towards other
excipients and active ingredients and not described in any
pharmacopeias, it was not a reasonable choice for pharma-
ceutical development. Oleylamine is another cationic lipid
that has been used to manufacture ophthalmic emulsions
[30], but this lipid also has stability concerns due to its
primary amine function and the presence of an unsaturated
site in the aliphatic chain.
Other cationic molecules usually used for DNA trans-
fection are also frequently used for the formulation of
cationicdrugdeliverysystems:poly(ethylenimine) (PEI)and
poly-L-lysine (PLL). PEI is an organic polymer that has a
high density of amino groups that can be protonated. At
physiological pH, the polycation is very eﬀective in binding
DNA and can mediate the transfection of eukaryotic cells
[31]. It has been used as a cationic agent in micelles [32],
nanoparticles [33], albumin nanoparticles [34], liposomes
[35], and nanosized cationic hydrogels [36]. However, while
some authors claim this polymer to be safe some others such
as Hunter [37]h a v er e p o r t e dP E It ob ee x t r e m e l yc y t o t o x i c .
PLLisapolymermadeofseverallysines(aminoacid).LysineJournal of Drug Delivery 5
possesses a NH2 function which is ionized at a physiological
pH conferring several cationic charges to that polymer. It is
sometimes used as cationic agent in drug delivery systems
such as microparticles [38]. However, toxicity has been
reported [39], and this polymer is not authorized for use in
ophthalmic formulations.
Cationic lipids, DOTAP (N-(1-(2,3-dioleoyloxy)
propyl)-N,N,N trimethylammonium) chloride and DOPE
(dioleoyl phosphatidylethanolamine), represent another
potential class of cationic agents. These are amphiphilic
molecules with a fatty acid chain and a polar group bearing
a cationic charge. Their main advantage is that they are
biodegradable and well tolerated. DOPE, which also harbors
a negative charge, is a neutral “helper” lipid often included
in cationic lipid formulations like cationic nanoemulsions
[40]. Cationic solid lipid nanoparticles were successfully
made with DOTAP to transport DNA vaccines [41]. Hagigit
and colleagues [42, 43] showed that using DOTAP was better
than the seminatural lipid oleylamine to make stable cationic
emulsions. Moreover, DOTAP cationic emulsion enhanced
the penetration of antisense oligonucleotides after either
topical ocular instillations or intravitreous injection. But like
most of the seminatural lipids, these agents are chemically
unstable and need to be stored at −20◦C, thus drastically
limiting their industrial use.
The primary limiting factors against the use of the
previously cited cationic agents in the Novasorb technology,
even though they showed potential in the formulation of
cationic drug delivery systems, is that (1) they are not listed
in US and EU pharmacopeias or (2) their toxicity on the
ocular surface has not been well documented, and (3) none
ofthesecationic agentshasbeen successfullycommercialized
in a pharmaceutical product. Consequently, Novagali chose
to limit its search for the appropriate cationic agent among
those already registered, used in ophthalmic products, or
compliant to pharmacopeias.
Other excipients previously accepted by health authori-
ties were then considered. Quaternary ammoniums usually
u s e da sp r e s e r v a t i v e sh a v es u r f a c t a n tp r o p e r t i e sa n dt h e
potential to give a cationic charge to the nanoemulsions.
These agents include cetrimide, benzalkonium chloride,
benzethonium chloride, benzododecinium bromide, and
cetylpyridinium. As preservatives these products protect
against infectious contaminants by electrostatically binding
tothenegativelychargedsurfaceofbacteriaandmycoplasma
and disrupting their cell membranes. The disadvantage
of quaternary ammoniums is that their eﬀect on cell
membranes is not limited only to microorganisms but
they are also capable of injuring epithelial cells lining the
ocular surface by the same mechanism of action. It was
consequently not obvious to foresee these molecules as
cationic agents, therefore, quaternary ammoniums were not
initially considered for use in emulsions. In 2002, Sznitowska
revealed ﬁndings that the preservative eﬃcacy of this class
of surfactants was diminished or neutralized in the presence
of emulsions [44]. Part of the quaternary ammonium is
bound to the emulsion, resulting in the presence of less
free surfactant molecules in the aqueous phase to exert
their antimicrobial action, and, consequently, their toxic
Table 3: Excipients which can be used in an ophthalmic emulsion.
Function Excipients
Osmotic agents Mannitol, glycerol, sorbitol, propylene
glycol, dextrose
Oils Medium chain triglycerides, mineral
oil, vegetal oil such a castor oil
Cationic agents
Benzalkonium chloride,
cetylpyridinium chloride, cetrimide,
benzethonium chloride
Surfactants
Polysorbates, cremophors,
poloxamers, tyloxapol, vitamin
E-TPGS
Buﬀers, salts,
and anions To be avoided if possible
Water Water for injections
Others
Viscosifying agents: preferably neutral
Preservatives: preferably nonionic and
hydrophilic
eﬀect on the ocular surface epithelia. Novagali Pharma
exploited this physicochemical property to make a new type
of cationic nanovector using benzalkonium chloride (BAK)
and cetalkonium chloride (CKC) as cationic agents. CKC
is a highly lipophilic (logP = 9.5) component of BAK.
It is hence mostly included in the oily phase providing a
higher zeta potential on surface of the oil droplets while
leaving relatively no free molecules to induce ocular surface
toxicity. BAK (and CKC as a component of BAK) has been
routinely used as a preservative in other marketed eye drop
solutions (e.g., BAK is used in Xalatan) and is accepted
as compliant with regulatory requirements for ophthalmic
products. These excipients used in lower concentrations as
cationic agents in emulsions have been demonstrated to be
safe for the eye as we will see in the toxicology chapter of
this article. More importantly, the use of BAK and CKC
as cationic surfactants only in emulsions are now protected
by several granted and pending European and US patents
(e.g.,EP1655021[25],EP1809237[45],EP1809238[46],and
EP1827373 [47]w h i c ha r eg r a n t e d ) .
3.2. Other Formulation Issues. Following the choice of the
cationic agent, other excipients, that is, nonionic surfactants,
osmotic agents, and oils, need to be selected and their
appropriate concentration decided (Table 3). The excipients
authorized for ophthalmic use are quite numerous and this
step of screening was mainly time dependent. An emulsion
is a system which is by essence unstable. The stability
is further ensured by the combination of excipients with
the surfactants; this combination also deﬁnes the size of
the emulsion. The concentration of surfactants should be
a compromise between stability and toxicity. The most
commonly used surfactants are poloxamers, polysorbates,
cremophors, tyloxapol, and vitamin E TPGS.
To choose the appropriate excipients and their concen-
tration, parameters like the ﬁnal osmolality and pH of the
nanoemulsion need to be considered. The product to be
appliedontheeyesurfaceshouldhavetheseparametersclose6 Journal of Drug Delivery
to physiological values. This introduces another diﬃculty
as the buﬀers and osmotic agents may also hide the
surface charge of the cationic nanodroplets and potentially
destabilize the emulsion. Normal tears have a pH between
6.9 and 7.5 [48]. The literature indicates that the ocular
instillation of 20µLo fab u ﬀered solution at pH 5.5, 0.067M
isquicklybroughttopH6–6.5inthetears[49].Furthermore,
it is usually known that a low pH is well tolerated if it is
r a p i d l yb r o u gh tb a c kt on o r m a lt e a rp H[ 50], therefore it can
be assumed that buﬀering is not so important. In the case of
Novasorb, the emulsion can be slightly buﬀered with a tris
buﬀer (Cationorm) or not buﬀered at all, leaving the natural
pH of the mixture. In that case, the tears rapidly restore the
physiological pH of the lacrimal ﬁlm.
Neutral osmotic agents, such as polyols (glycerol, man-
nitol, or sorbitol) were used. The lipid emulsions more or
less physically resemble a simple aqueous-based eye drop
dosage forms since more than 90% of the external phase is
aqueous irrespective of the formulation composition. The
main diﬀerence is its visual aspect: a milky white appearance.
The ﬁnal speciﬁcations are summarized in Table 4. It should
be noted that even though BAK or CKC is present in the
product as the cationic agent, the formulations are not
preserved [51]. Thus, emulsions are packaged in single use
vials ﬁlled by the Blow-Fill-Seal technology. Finally, the
vehicle typically has a formula as presented in Table 5.A c t i v e
ingredient is added in the oily phase but some hydrophilic
molecules could be added in the aqueous phase to create a
combination product.
T h es i z eo ft h eo i ln a n o d r o p l e t si so fu t m o s ti m p o r t a n c e
as it contributes to the stability of the emulsion and to the
ocular absorption. To our knowledge, it has not yet been
demonstrated that ocular absorption is correlated to the
size of the nanovectors even if it is logical that the smaller
the object, the higher the expected uptake. As discussed by
Rabinovich-Guilatt et al. [21], there are several mechanisms
of absorption of nanoparticles in the cornea. In the case
of cationic nanoemulsions, positively charged nanodroplets
of oil are not likely to penetrate the cornea as the drops
are bound to the negatively charged mucus. Therefore, the
delivery of the active ingredient is probably related to a
passive diﬀusion linked to the enhanced retention time.
Anadditionalfactorfavoringdrugabsorptionislinkedto
the small size of the nanodroplets, that is, the interfacial area
available for drug exchange. If the mean diameter of an oil
droplet is 150nm, and the volume of emulsion administered
on the ocular surface is about 30µL, the number of oil
nanodroplets administered is close to 1010. Consequently,
with such an extraordinarily elevated speciﬁc surface of
exchange (almost 1,000mm2) the diﬀusion of the active
ingredientstothetargetedtissuesisgreatlyimproved.Thus,a
small droplet size of the nanoemulsion should consequently
be associated with an improved clinical eﬃcacy of the drug.
The manufacturing process is a three-step process as
described in Figure 2. The ﬁrst step is a phase mixing under
magnetic stirring at 100rpm for a few minutes followed
by a high shear mixing at 16,000rpm during 10min at
that stage the oil droplets of the emulsion have a size of
Table 4: Final speciﬁcations of the cationic nanoemulsions.
Speciﬁcations Values
Aspect Milky white to translucid
pH 5.5–7
Osmolality 180 to 300mOsm/kg
Zeta potential +20 to +40mV
Mean oil droplet size 150 to 300nm
Sterility Sterile
Viscosity 1.1m2/s
Surface tension Similar to tears: 41mN/m
approximately 1µm. To reach a submicronic size (150–
200nm) the emulsion is submitted to a high pressure
homogenization at 1,000 bars under cooling.
Stable cationic nanoemulsions were selected over hun-
dreds of prototypes after being submitted to screening stress
tests (freeze/thaw cycles, centrifugation, and heat test at
80◦C). In addition, a deep physicochemical characterization
including measurement of pH, osmolality, zeta potential,
droplets size, interfacial and surface tension, aspect, and
viscosity wassystemicallyperformedonprototypes. Allthese
tests are able to discriminate a potential destabilization of the
emulsions like creaming, coalescence Ostwald ripening, and
phase separation and to set ﬁnal speciﬁcations of the drug
product as described in Table 4.
Finally, the product should be sterile. Since the steril-
ization process can have a major impact on the physical
integrity of the emulsion, it should be taken into account at
an early stage during the development of the formulation. A
sterilizing ﬁltration is not possible for emulsions as it uses a
ﬁlter with 0.22µm size pores that can clog during ﬁltration.
Aseptic processes are too expensive. The remaining option
was heat sterilization; however, this can be performed only
on very stable emulsions, and hence the need of a careful
choice of the above-mentioned excipients.
3.3. Drug Loading. The Novasorb technology platform was
ultimately designed to be loaded with active molecules.
Emulsions are clearly adequate forlipophilic drugs with a log
Po f2 - 3( P :o c t a n o l / b u ﬀer pH 7.4 partition coeﬃcient) pref-
erentially nonionizable, and such candidates are numerous.
Evenso,thecationicemulsionwithnoactiveingredientitself
possesses beneﬁcial properties. Its composition comprising
oil, water, surfactants, and glycerol reduces evaporation of
tears from the ocular surface while lubricating and moistur-
izing the eye. Altogether the components confer a protective
eﬀect by augmenting each layer of the tear ﬁlm. Based on
theinherentpropertiesoftheNovasorbtechnology,restoring
the deﬁcient layers of the natural tear ﬁlm, Cationorm,
a preservative-free cationic emulsion containing no active
ingredient, has been commercialized globally for the relief of
dry eye symptoms (Table 6).
Nearly 40% of new chemical entities have a low aqueous
solubility, therefore potential candidates to be loaded into
Novasorb [52]. Novagali Pharma incorporated about 40
lipophilic active ingredients of various therapeutic classesJournal of Drug Delivery 7
Table 5: Composition of a typical vehicle from Novasorb technology.
Excipients Function Concentration %
w/w
Oily phase
Medium chain triglyceride Internal phase 1 to 2
Cetalkonium chloride Cationic agent 0.005
Tylopaxol Surfactant 0.2
Aqueous phase
Poloxamer 188 Surfactant 0.01
Glycerol Osmotic agent 1.5 to 2.5
NaOH pH adjuster Ad pH 6-7
Water for injections External phase Ad 100
(3) High pressure homogenization
at 1,000 bars
> 1 µm
(1) Phase mixing at 100 rpm
(2) High shear mixing at 16,000 rpm
≈ 1 µm
150–200 nm
Figure 2: Three manufacturing steps of the process necessary to decrease the oil droplet size of the emulsion. Optical microscopy pictures
of the emulsions are presented.
(NSAID, SAID, antibiotics, antifungals, etc.) proving the
versatility of this emulsion. Herein, we will only focus on the
most advanced products. Despite topical administration in
solvents yielding poor bioavailability, CsA, a very lipophilic
immunomodulatory drug, is widely used by ophthalmolo-
gists due to its recognized therapeutic potential for the treat-
ment of ocular diseases (dry eye, allergy, and inﬂammation)
[53]. CsA was considered an excellent initial candidate to
evaluate the potential of the Novasorb cationic emulsion to
improve the eﬃcacy of an established drug. Therefore, the
primary challenge in the development of a cationic emulsion
containing CsA was to design the optimal formulation [53]
for topical delivery. Today, Novagali Pharma has developed
two products based on the Novasorb technology loaded with
CsA: Cyclokat for the treatment of dry eye and Vekacia for
the treatment of vernal keratoconjunctivitis.
Latanoprost, a lipophilic prostaglandin analogue, is a
potent intraocular pressure lowering agent currently mar-
keted as Xalatan (Pﬁzer,) for the treatment of glaucoma
and ocular hypertension. In Xalatan, the active ingredient,
latanoprost 0.005%, is solubilized in water by 0.02% of BAK.
Despite being the leading antiglaucoma medication, there
are two drawbacks of Xalatan that may have impacted its
huge commercial success: (1) the formulation was not stable
at room temperature necessitating storage at 5◦Ca n d( 2 )
BAK in the formulation as a preservative and solubilizing
agent causes ocular surface toxicity which probably resulted
in decreased compliance. As the patent protecting this
molecule is expiring in 2011, there was an opportunity to
improve upon the disadvantages of Xalatan. Hence, Novagali
launched the development of Catioprost, a preservative-free
cationic emulsion loaded with latanoprost for the treatment
of elevated intraocular pressure (IOP) while protecting and
improving the ocular surface.
4. NonclinicalDevelopment
The nonclinical development is divided into the safety
evaluation and the pharmacokinetic studies.
4.1. Safety. Establishing the safety of the new nanotechnol-
ogy was an important goal of the nonclinical development
program. Toxicity is a major concern in nanotechnology as
the behavior of the nano-object is diﬃcult to predict [4].8 Journal of Drug Delivery
Table 6: Main product based on Novasorb technology marketed or to be marketed.
Product Active ingredient Indication Status
Cationorm Medical device Dry eye Marketed
Cyclokat 0.1% cyclosporine A Severe dry eye Phase III
Vekacia 0.1% cyclosporine A Vernal
keratoconjunctivitis Phase III
Catioprost 0.005% latanoprost Glaucoma associated with
ocular surface disease Phase II
Therefore, numerous studies were conducted to ensure the
ocular safety of the cationic emulsion.
As the active ingredients used in Novagali’s emulsions
(CsA and latanoprost) are already used in other drug
products only the toxicity of the vehicle and the ﬁnal product
was evaluated.
Before the development of Novasorb, preliminary data
regarding the ocular safety of some cationic emulsions on
the eye were already available [54]. A subchronic toxicity
study performed in rabbits demonstrated that a cationic
emulsion containing 3mg/mL stearylamine was found to
be safe and well tolerated after repeated topical ocular
administrations [54]. In addition, a local tolerance study
in rabbit eyes demonstrated that a 1mg/mL oleylamine
ophthalmic emulsion instilled eight times per day for 28
days was relatively well tolerated [21]. These data, even
though promising, were not suﬃcient to support further
development as Novasorb utilizes cationic agents (CKC
and BAK) that are usually used at higher concentrations
as preservatives. The safety proﬁle of Novasorb cationic
emulsions using BAK as a cationic agent was thus evaluated
in both in vitro and in vivo models as listed in Table 7.
4.1.1. Safety of Novasorb as Vehicle. During the formulation
work, emulsion prototypes were quickly evaluated by the
Draize test which, despite a few limitations, allowed the
identiﬁcation of the least irritating nanoemulsion. This test
consists of instilling 30 to 50µL of the product into one eye
of 6 New Zealand white rabbits and monitoring to observe
any abnormal clinical signs such as redness of conjunctiva,
swelling, or increased blinking which may indicate irritation.
T h et e s td o e sn o tg i v eo b j e c t i v ev a l u e sa si ti so p e r a t o r
dependent but gives a good idea of how the product will be
tolerated.
Other in vitro and in vivo tools were used. In an in vitro
scrapping assay using human corneal epithelial (HCE) cell
monolayers, a cationic emulsion containing 0.02% BAK as a
cationic agent was as well tolerated as a phosphate buﬀered
saline (PBS) solution while an aqueous solution of 0.02%
BAK revealed toxicity.
An acute toxicity rabbit model was used which allows for
the characterization of the mechanism underlying the toxic-
ity observed during the conventional Draize tests [55]. In the
experiment,15instillationsoftesteyedropsareadministered
at 5min intervals, with observations performed over 96
hours. Clinical signs, in vivo confocal microscopy, and
conjunctival impression cytology were performed to assess
Table 7: Listing of safety screening and regulatory toxicity studies
performed in order to test Novasorb technology in humans.
Nonclinical
studies type
Safety studies for Novasorb alone
and loaded Novasorb
Safety screening
(i) Draize test
(ii) Demonstration in a repeated acute
rabbit toxicity model that BAK and CKC
containing emulsion are well tolerated
(iii) Ocular safety evaluation of newly
developed in vitro corneal wound healing
model and in an acute in vivo rabbit model
(iv) In vivo toxicity evaluation of latanoprost
cationic emulsion in the rabbit
Regulatory toxicity
studies
(i) In vitro evaluation of the cytotoxic
potential by indirect contact
(ii) Delayed-type hypersensitivity evaluation
in the Guinea pig
(iii) Ocular irritation test in the rabbit (short
term: 72h) following a single application
(iv) Determination of the physical
compatibility of Novasorb with contact
lenses
(v) 28-day ocular tolerance in the rabbit
(vi) Evaluation of the potential to induce
delayed contact hypersensitivity (local
lymph node assay)
(vii) Evaluation of the corneal sensitivity
following repeated applications in albino
rabbits
(viii) Phototoxicity and photoallergic
potential evaluation following topical
applications in the Guinea pig
(ix) 6-month ocular toxicity in the dog and
rabbit
the safety proﬁle of the diﬀerent cationic emulsions with
BAK or CKC as the cationic agent. This study demonstrated
that cationic emulsions using BAK or CKC as the cationic
agent were very well tolerated while the tested 0.02% BAK
solution was responsible for corneal epithelial cell death
related to the proinﬂammatory and proapoptotic activity of
BAK.
4.1.2. Safety of Novasorb Loaded with Active Ingredients.
The safety proﬁle of the Novasorb used as a vehicle for
lipophilic drugs such as cyclosporine (Vekacia/Cyclokat) andJournal of Drug Delivery 9
latanoprost (Catioprost) was evaluated in animal models
[56]. These studies demonstrated that neither of the two
active ingredients (CsA or latanoprost) has an impact on the
safety proﬁle of the cationic emulsions as both drug-loaded
cationic emulsions were as well tolerated as the cationic
emulsion vehicle (Figure 3). For example, in the acute tox-
icity rabbit model, repeated instillations of Cyclokat/Vekacia
(CsA-containing 0.05 and 0.1% CsA cationic emulsions)
were as well tolerated as Restasis (0.05% CsA anionic
emulsion), and Catioprost (preservative-free latanoprost
0.005% cationic emulsion) was better tolerated than the
0.02% BAK-preserved Xalatan. Local tolerance studies in
the rabbit conﬁrmed that chronic instillations (4–6 times
daily over 28 days) with Cyclokat/Vekacia and twice daily for
Catioprost were well tolerated by the rabbit eyes.
All the previous in vivo data were obtained in rabbits
with a healthy ocular surface. However, it was of interest to
also assess the eﬀect of Catioprost on damaged corneas to
more closely mimic the clinical situation experienced when
elderly patients are started on glaucoma therapy. For that
purpose, a rat model of debrided cornea was used to assess
theeﬀectofCatioprost,itsemulsionvehicle,andXalatan(the
commercially available product of latanoprost) on the ocular
surface healing process. The in vivo data demonstrated that
Xalatan delayed corneal healing, while both Catioprost and
itscationicemulsionvehicle(withoutlatanoprost)promoted
healing of the ocular surface and restored the function of the
injured epithelium, thus conﬁrming the better safety proﬁle
of the Novasorb cationic emulsions and conﬁrming that
Novasorb could hasten the repair of ocular surface damage.
Novasorb was hence shown to be safe, but prior to human
testing several other studies were necessary to fulﬁll the
various European and American guidelines. These studies
cited in Table 7 included in vitro evaluation of the cytotoxic
potential by indirect contact, a delayed-type hypersensitivity
evaluation in the guinea pig, an ocular irritation test in
the rabbit (short term: 72h) following a single application,
a determination of the physical compatibility of Novasorb
with contact lenses, a 28-day ocular tolerance in the rabbit,
an evaluation of the potential to induce delayed contact
hypersensitivity (local lymph node assay), an evaluation of
the corneal sensitivity following repeated applications in
albino rabbits, an evaluation of potential phototoxicity and
photoallergy following topical applications in the guinea pig
and ﬁnally a 6-month ocular toxicity in the dog and rabbit.
The description of these entire assays can be found in the
various regulatory guidelines.
4.2. Proof-of-Concept Studies and Pharmacokinetics. In par-
allel to ensuring the safety, proof-of-concept studies were
performed in order to validate the cationic nanoemulsion
technology in the ocular delivery of active molecules.
To assess the eﬀect of the cationic charge on the ocular
surface, Novagali Pharma has performed static and dynamic
contact angle and surface tension studies on harvested rabbit
eyes according to a method adapted from Tiﬀany [57]. This
experiment showed that Novasorb cationic emulsions have a
better spreading coeﬃcient on the cornea and conjunctiva
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Figure 3: In vivo confocal microscopy score of rabbit ocular surface
following repeated instillations with Novasorb cationic emulsion of
latanoprost. IVCM images of rabbit ocular surface and conjunctiva
associated lymphoid tissue (CALT) were used to assess the safety
of the cationic emulsion of latanoprost by scoring the alterations
observed following repeated instillations. Note that the lower the
score the better the tolerance. PBS was used as a negative control.
(∗) P<0.0001 compared with 0.02% BAK-latanoprost (0.005%).
Adapted from Liang et al. [56].
than conventional eye drops and anionic emulsions. This
improved spreading coeﬃcient leads to better ocular surface
wettability. Optimal spreading of the cationic emulsion
confers protective ﬁlmogenic properties and reduces tear
washout. Figure 4 illustrates the behaviour of the cationic
emulsion which spread over the eye very rapidly compared
to other formulations. It has been well described that oil-
in-water emulsions enhance drug absorption by facilitating
corneal or conjunctival absorption or prolonging the contact
with the eye, thus improving drug delivery [58].
Early pharmacokinetic studies were performed to evalu-
ateCsAabsorptionfollowingtheapplicationofexperimental
0.2% CsA cationic and anionic emulsions [19]. The data
demonstrated that the cationic emulsion was almost two-
times better at delivering CsA to ocular tissues than an
anionic emulsion, even though the latter contained 0.01%
BAK and 0.2% deoxycholic acid as a mild detergent that can
disrupt cell membranes and serve as a permeation enhancer.
Restasis (Allergan) is an anionic emulsion of CsA
(0.05%) that has been shown to readily penetrate ocular
tissues without signiﬁcant systemic passage [59, 60]. Phar-
macokinetic(PK)studiesdesignedtoevaluatetheocularand
systemic CsA distribution following single and multiple dos-
ing with cationic emulsions NOVA22007 (cationic emulsion
at0.05%)orCyclokat(cationicemulsionat0.1%),compared
to Restasis as a reference, conﬁrmed the beneﬁcial role of the
cationic charge in enhancing the ocular penetration of CsA
[61] in Novasorb cationic emulsions.
Single-dose PK data demonstrated that the 0.05% CsA
cationic emulsion was more eﬀective than Restasis at deliver-
ing CsA to the cornea (Cmax: 1372 versus 748ng/g; AUC:
26477 versus 14210ng/g.h, resp.). Furthermore, multiple-
dose PK conﬁrmed that there was no systemic absorption,10 Journal of Drug Delivery
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Figure 4: Dynamic contact angle measurement and base width of an eye drop instilled on rabbit eyes. Photos taken at 0, 0.66, 1.33, 3.32
secondsafterinstillationofhyaluronatehydrogel(Hylo-COMOD),anionicemulsion(RefreshEndura),andcationicemulsion(Cationorm).
Contact angle and base width values conﬁrm the optimal and fasted spreading of cationic emulsions compared to anionic emulsions and
hyaluronic acid based product.
withvaluesbelowthelimitofdetection(LOD,0.1ng/mL)for
theCsA-cationicemulsion(seeFigure 5).Theuseof3H-CsA
also demonstrated that the systemic distribution following
repeated instillations was indeed low and comparable for
both the CsA-cationic emulsion and Restasis and conﬁrmed
that the improved local absorption with the CsA-containing
cationic emulsion did not translate into increased systemic
CsA levels.
In addition, the electroattractive interactions between
the positively charged oil droplets of the cationic emulsion
and the negatively charged ocular surface cell epithelia
might also explain the 50% lower contact angle observed
with cationic emulsions versus anionic (negatively charged)
emulsions, and the higher spreading coeﬃcient [18]. A low
contact angle, better spreading coeﬃcient, and an increased
residence time of the cationic emulsions may all contribute
to the better drug absorption of lipophilic drugs solubilized
in cationic emulsions.
The cationic emulsions designed for the treatment of
dry eye disease (Cyclokat) and vernal keratoconjunctivitis
(Vekacia) were not tested in pharmacodynamic models
as there are no reliable experimental models for these
pathologies. However, pharmacokinetic studies with CsA
cationic emulsions in animal models demonstrated (see
previous paragraph) that the tissue concentrations of CsA
were above the therapeutic concentration (50–300ng/g of
tissue according to Kaswan [62]) in both the cornea and
conjunctiva. Therefore, the safety and eﬃcacy of these CsA-
containing cationic emulsions were ﬁrst demonstrated in
phase II and III clinical trials (see the following section).
In contrast, the safety and eﬃcacy of Catioprost
(preservative-free latanoprost 0.005% cationic emulsion)
was initially evaluated in an established cynomolgus monkey
modelofocularhypertension[63],andcomparedtoXalatan.
Both latanoprost formulations shared the same eﬃcacy
proﬁle, and the intraocular pressure (IOP) reduction lasted
24h. Additionally, a comparison of the local tolerance of
Catioprost and Xalatan following twice-daily repeated instil-
lations in rabbits over a 28-day period revealed, although
both products were well tolerated, there was a 42% lower
incidence of conjunctival redness in rabbits treated with
Catioprost. Overall, the results of the preclinical models
suggested that Catioprost appears to be as potent as Xalatan
for the reduction of IOP with an improved safety proﬁle.
As listed in Table 8, some pharmacokinetic studies are
compulsory prior to human testing. They include the
single- and multiple-dose pharmacokinetic studies, the
determination of systemic exposure, plus the toxicokinetic
studies following repeated instillations. The full nonclinical
package gave a high conﬁdence that Novasorb technology
alone or loaded with active ingredients was fully safe and
could provide high concentration of active ingredient in
ocular tissues. The next step of the development was then the
clinical evaluation in human.
5.ClinicalDevelopment
An IND-enabling dossier was prepared allowing for conduct
of a ﬁrst-in-man clinical trial. This dossier was prepared
according to guidance received through regulatory inter-
actions with health agencies (FDA, EMA). Indeed, early
exchanges with health agencies about technologies are pos-
sible to discuss technology speciﬁc requirements (eﬃcacy,
safety) and anticipated clinical and regulatory development
programs.Journal of Drug Delivery 11
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Figure 5: (a) Changes in corneal CsA concentration with time after
a single unilateral topical administration in pigmented rabbits. The
error bars represent standard errors. (b) Cornea absorption (AUC)
following a single instillation in pigmented rabbits.
Table 9 describes thediﬀerentclinical trials carried outto
the evaluate Novasorb technology with or without an active
ingredient. The clinical development was ﬁrst performed
with a drug-free cationic emulsion formulation (vehicle).
Theﬁrstclinicaltrialwascarriedoutwiththeﬁrstgeneration
of the cationic emulsion in 16 healthy volunteers. The safety
and tolerance of four-times daily instillations was evaluated
over 7 days of treatment. The product was shown to be
safe and well tolerated. Since the vehicle harbors intrinsic
properties of ocular surface protection, it was then tested in
two phase II clinical trials aiming at evaluating the eﬃcacy,
tolerance, and safety of Cationorm in patients with mild to
moderate dry eye (results are detailed in the next section).
A cationic emulsion containing CsA was subsequently
evaluated in patients with either dry eye disease (DED)
or vernal keratoconjunctivitis (VKC). Highlights of some
Table 8: Listing of proof-of-concept and regulatory pharmacoki-
netics studies performed in order to test Novasorb technology in
humans.
Nonclinical
studies type
Studies for Novasorb alone
and Novasorb loaded
Proof-of-concept
(i) Ex vivo measurement of contact angle
and surface tension of cationic emulsions on
rabbit eyes
(ii) Evaluation and comparison of the
wound healing potential of the cationic
emulsion versus artiﬁcial tears in a rabbit
model of corneal abrasion
(iii) Evaluation of the eﬃcacy of a 0.1%
cyclosporine A cationic emulsion in the
management of keratoconjunctivitis sicca in
the dog
(iv) Evaluation of the eﬃcacy of a cationic
emulsion of 0.005% latanoprost at reducing
elevated intraocular pressure in
glaucomatous monkeys
(v) In vitro and in vivo evaluation of a
preservative-free cationic emulsion of
latanoprost in corneal wound healing
models
Regulatory
pharmacokinetics
studies
(i) Single and multiple doses
pharmacokinetic
(ii) Systemic exposure determination and
toxicokinetics following repeated
instillations of BAK and CKC-containing
cyclosporine A cationic emulsion
clinical results are detailed below in light of challenges faced
including eﬃcacy of the “placebo” comparator which was
the cationic emulsion vehicle, variability of endpoints, and
disconnection between sign and symptoms of ocular surface
diseases.
Finally, a phase II program was initiated with Catioprost,
thecationicemulsioncontaininglatanoprost.Sincethephase
II trial is ongoing, no data are available.
5.1. Clinical Evaluation of Cationorm. In the 2007 Dry Eye
Workshop (DEWS) report, dry eye disease (DED) is deﬁned
as a multifactorial disease of the tears and ocular surface
that results in symptoms of discomfort, visual disturbance,
and tear ﬁlm instability with potential damage to the ocular
surface. Currently, symptomatic treatment with artiﬁcial
lubricants is the ﬁrst line of treatment for patients with DED;
however,thedisadvantageofmostconventionalartiﬁcialtear
solutions is that most of the instilled drug is lost within the
ﬁrst 15–30 seconds after installation, due to reﬂux tearing
and the drainage via the nasolacrimal duct. The prolonged
residence time of the cationic emulsion on the ocular surface
due to the electrostatic attraction between the positively
chargedlipidnanodropletsandthenegativelychargedocular
surface and the augmentation of the tear ﬁlm layers by the
oily and aqueous phase of the emulsion suggested that the
Novasorb technology could be inherently beneﬁcial for the
ocular surface even in the absence of an active ingredient.12 Journal of Drug Delivery
Table 9: Clinical trials performed with Novasorb.
Year Phase type Product Objectives Indication No. of patients
2003 Phase I Vehicle no.1 Tolerance and safety None 16
2004 Phase II Tolerance and safety,
Exploratory eﬃcacy Dry eye 50
2005 Phase II Cationorm
(Vehicle no.2)
Eﬃcacy, tolerance, and
safety Dry eye 79
2010 Phase II Eﬃcacy, tolerance, and
safety Dry eye 71
2005 Phase IIa
Cyclokat
Tolerance and safety
Exploratory eﬃcacy Dry eye disease 48
2008 Phase IIb Exploratory eﬃcacy,
tolerance, and safety Dry eye disease 132
2009 Phase III “Siccanove” Eﬃcacy, tolerance, and
safety Dry eye disease 496
2011 Phase III “Sansika” Eﬃcacy, tolerance, and
safety Dry eye disease 252
2006 Phase IIb/III Vekacia
Eﬃcacy, tolerance, and
safety Active VKC 118
2009 Phase IIb Eﬃcacy, tolerance, and
safety Nonactive VKC 34
2011 Phase II Catioprost
Exploratory eﬃcacy,
open-label study Glaucoma NA
2011 Phase IIb Exploratory eﬃcacy,
tolerance, and safety Glaucoma 100
VKC: Vernal keratoconjunctivitis.
Consequently, the ocular tolerance and eﬃcacy of
Cationorm, a preservative-free cationic emulsion, were
evaluated and compared to Refresh Tears (Allergan) in a
one-month, phase II, multicenter, open-label, randomized,
parallel-group study enrolling patients with signs and symp-
toms of mild to moderate DED. Adults with a history of
bilateral DED were subjected to a washout period of prior
DED treatments during which only artiﬁcial tears were
allowed. At the inclusion visit patients were randomized
to treatment with either Cationorm (n = 44) or Refresh
Tears (n = 35) in both eyes 4 times daily and evaluated
at follow-up visits on Day 7 and Day 28. Ocular tolerance
and eﬃcacy were assessed at one month. Seventy-nine
patients, 86% female with a mean age of 61.6 years, were
enrolled in the study. At 1 week and 1 month the mean
reduction in individual dry eye symptoms scores and total
dry eye symptoms scores were greater in the Cationorm than
Refresh Tears treated patients (36% versus 21% at Day 7,
and 49% versus 30% at Day 28, resp.) demonstrating that
DED symptoms improved better with Cationorm. While
the global local tolerance was perceived similarly with both
treatments, the study investigators rated the overall eﬃcacy
of Cationorm statistically signiﬁcantly better than Refresh
Tears (P<0.001). Additionally, Cationorm-treated patients
experienced greater improvements from baseline compared
to Refresh Tears-treated patients for the Schirmer test (1.88
versus 1.27mm) and corneal ﬂuorescein staining (−0.61
versus −0.59) with statistically signiﬁcant improvements in
the tear ﬁlm break-up time (2.00 versus 1.16, P = 0.015) and
lissamine green staining (−1.42 versus −0.91, P = 0.046).
The overall results showed that Cationorm was as safe as,
but more eﬀective than, Refresh Tears in patient with mild
to moderate DED symptoms.
In a subsequent 3-month, controlled, randomized,
single-masked study conducted in Italy, the eﬃcacy of
Cationorm was evaluated in adults with moderate dry eye
[64]. Seventy-one patients were randomized to treatment
withCationorm,Optive(Allergan),orEmustil(SIFI)4times
daily, and eﬃcacy assessments were conducted at 1 and
3 months. At 1 month patients treated with Optive and
Cationorm experienced a statistically signiﬁcant improve-
ment from baseline in their dry eye symptoms which was
also evident for each of the 3 treatment groups at 3 months.
At 3 months, improvements from baseline in the tear break-
up time and ﬂuorescein staining were statistically signiﬁcant
for Cationorm and Optive but not for Emustil, and while
both Cationorm and Optive signiﬁcantly reduced tear ﬁlm
osmolarity, only Cationorm showed a statistically signiﬁcant
change compared to Emustil. In this study Cationorm
was clearly more eﬀective than Emustil in patients with
moderate DED and although not statistically better, the
overall improvement in DED symptoms and signs were
greater in patients treated with Cationorm than Optive.
The results of the preclinical studies (corneal healing in
alkali burn and de-epithelization rabbit models) and clinical
trials evaluating Cationorm in patient with DED support its
safetyandeﬃcacyforthetreatmentofdryeyesymptomsand
showed the beneﬁt of the Novasorb cationic emulsion on the
ocular surface independent of an active ingredient. However,
as we will see, the inherent eﬃcacy of the preservative-freeJournal of Drug Delivery 13
cationic emulsion on improving symptoms of ocular surface
disease presented an unanticipated challenge when used as
a vehicle in the evaluation of the eﬃcacy of the preservative-
freecationicemulsionloadedwithCsAinpatientswithDED.
5.2. Clinical Evaluation of Cyclokat. In the DEWS deﬁnition
of DED it is stated that DED is accompanied by an
increasedosmolarityofthetearﬁlmandinﬂammationofthe
ocular surface. As such DED can be considered a chronic,
bilateral inﬂammatory condition for which appropriate
treatment, particularly for patients unresponsive to symp-
tomatic treatment with artiﬁcial tears would include an anti-
inﬂammatory agent. While Restasis, an anionic emulsion of
0.05% CsA, is available for the treatment of DED in the US,
despite the widespread use of hospital compounded CsA and
even corticosteroids in the EU there has been no approved
pharmaceutical drug indicated for patients with DED. Based
on the preclinical data showing the potential advantages
of a cationic emulsion over anionic emulsions and unmet
medical need for an approved topical CsA formulation in the
EU, Novagali undertook the development of Cyclokat for the
treatment of dry eye disease.
The initial clinical trial of Cyclokat was a phase II,
3-month, randomized, double-masked, placebo-controlled,
dose-ranging study enrolling 53 Gougerot-Sj¨ ogren patients
with moderate to severe DED. The primary objective of the
study was to assess ocular tolerance and systemic safety of
the cationic emulsion containing CsA at concentrations of
0.025%,0.05%,and0.1%comparedtothecationicemulsion
vehicle containing no active ingredient. An exploratory
evaluation of eﬃcacy was a secondary objective. At baseline,
62% of the enrolled patients had a Schirmer test score of
≤1mm at 5 minutes and 49% had a corneal ﬂuorescein
staining score of ≥3. Over the 3-month treatment period
there were no safety concerns and no evidence of systemic
absorption of CsA following topical administration of either
Cyclokat dose. Patients treated with the 0.1% Cyclokat
formulation showed greatest improvements in corneal and
conjunctival staining at 3 months and a dose response eﬀect
was observed for the reduction of conjunctival HLA-DR
staining (a biomarker for ocular surface inﬂammation) at
month 3 compared to baseline (vehicle: −10%; 0.025% CsA:
−8%; 0.05% CsA −23%, and 0.01% CsA: −50%).
A second phase II, 3-month, double-masked placebo
controlled study comparing Cyclokat 0.05% and 0.1% versus
its cationic emulsion vehicle was conducted in 132 patients
with mild to moderate DED utilizing the controlled adverse
environment chamber. In this study the eﬃcacy and safety of
Cyclokatwasassessedbytheevaluationofcoprimaryeﬃcacy
endpoints(cornealﬂuoresceinstainingasthesignandocular
discomfort as the symptom) at month 3 after and dur-
ing exposure to controlled adverse environment chamber,
respectively. Although superiority was not achieved for the
coprimary endpoints, there was an overall favorable safety
proﬁle and eﬃcacy was demonstrated for the improvement
of several secondary endpoints addressing DED signs and
symptoms with the results favoring the use of the 0.1% dose
for subsequent clinical development.
The Siccanove study was a 6-month phase III, multicen-
ter, randomized, controlled, double-masked trial of Cyclokat
0.1% administered once daily versus its emulsion vehicle
in 492 patients with moderate to severe DED. The primary
study objective was to demonstrate superiority of Cyclokat
on both a DED sign (mean changes in CFS using the
modiﬁed Oxford scale) and DED symptoms (mean change
in global score of ocular discomfort using a VAS). Following
a washout period during which only artiﬁcial tears were
allowed, patients were randomized at baseline to treatment
with either Cyclokat (n = 242) or its cationic emulsion
vehicle (n = 250) and evaluated at study visits at months
1, 3, and 6. As early as month 1 (P = 0.002), patients treated
with Cyclokat showed a statistically signiﬁcant improvement
in the mean change in CFS grade compared to the cationic
emulsion vehicle from baseline which continued to improve
from month 3 (P = 0.030) to month 6, the DED sign
coprimary eﬃcacy endpoint. The statistically signiﬁcant
improvements in CFS over 6 months (P = 0.009) were
complemented by a statistically signiﬁcant improvement in
lissamine green staining (P = 0.048) and a reduction in
HLA-DR expression (P = 0.022) [65]. Additional, post hoc
analysis of the Siccanove study data showed that the beneﬁt
of treatment with Cyclokat was greatest in patients with the
most severe keratitis (as deﬁned by CFS) at baseline (delta in
the mean change in CFS from baseline in CFS grade 2–4 =
0.22, P = 0.009; 3-4 = 0.32, P = 0.005; grade 4 = 0.77,
P = 0.001) [66]. Although there was a clinically relevant
improvement in DED symptoms from baseline the Cyclokat
andcationicemulsionvehicletreatmentarms,nostatistically
signiﬁcant diﬀerences were observed at month 6 for the
mean change in the global score of ocular discomfort, the
DED symptom coprimary eﬃcacy endpoint. However, there
was a statistically signiﬁcant improvement in symptoms for
patients achieving a ≥25% improvement in the VAS score
(50.21%versus41.94%,P = 0.048).Thediﬃcultyindemon-
strating the beneﬁt of Cyclokat over its cationic emulsion
vehicle was in part attributed to the eﬃcacy of the vehicle
itself in improving the symptoms of DED as demonstrated
in clinical trials for Cationorm. Additionally, the symptoms
coprimary endpoint result can be related to poor correlation
between dry eye disease signs and symptoms. At baseline in
the Siccanove study, while the mean VAS scores increased
with the severity of the CFS, the correlation between the
VAS score, as an expression of DED symptoms, and the
CFS grade, as an expression of a DED sign, at baseline was
low (Spearman’s correlation coeﬃcient = 0.23) due to the
widevariabilityintheseverityofpatientreportedsymptoms.
Similarly at month 6 the statistical correlation between mean
change in CFS grade and VAS score was low (Spearman’s
correlation coeﬃcient =0.094)withonlyapproximately68%
of patients showing concordance in the direction of change
in CFS grade and DED symptoms [65]. Although a poor
concordance between dry eye disease signs and symptoms
has been recognized in the literature, improvement in both
signs and symptoms is an expected outcome in randomized
clinical trials investigating new DED treatments. Hence
several drugs having shown promise for improving DED
have failed due to the inability to demonstrate a statistically14 Journal of Drug Delivery
Figure 6: Cationorm is the ﬁrst product marketed based on the
cationic emulsion technology.
signiﬁcant improvement in signs and symptoms of dry eye
disease using coprimary eﬃcacy endpoints.
Fortunately, sign and symptom composite responder
endpoints, used in registration trial supporting the approval
of new treatments for other chronic inﬂammatory diseases,
provide an alternate method to satisfy the requirement
of regulatory authorities. The methodological approach of
composite responder analysis avoids issues related to high
variability when following mean change of signs and symp-
toms as discontinuous variables. By focusing only on within-
patient’s improvements, the composite responder approach
could resolve the concern related to the poor correlation
between signs and symptoms in evaluating the eﬃcacy of
new treatment for DED. As such a pivotal phase III trial,
the Sansika study, utilizing a composite responder analysis
at month 6, has been initiated to evaluate the eﬃcacy of
Cyclokat in patients with severe dry eye disease.
6. Conclusion
Novasorb technology is a typical example of a breakthrough
formulation technology primarily developed by an academic
team and successfully translated to the patient. Eight years
were necessary for the ﬁrst product to reach the market.
With three products in the late stages of clinical development
and one product on the market, Novasorb has now proven
the concept that cationic nanoemulsions can eﬀectively treat
ophthalmic diseases with no toxicity (tested successfully in
over 1,000 patients) and several other advantages (Table 10).
Cationorm (Figure 6) was launched on the French market
April 2008 and at the time this article is written more than
550,000 units of treatment were sold in about 10 coun-
tries without any pharmacovigilance concerns. Cyclokat,
Vekacia, and Catioprost could reach the market within a
few years following the successful completion of pivotal
registration studies. The reasons for the success of the
Novasorb technology are multiple. Since the beginning of
theformulationwork,thecompanyprioritizedthesearchfor
only compoundial and ophthalmology accepted excipients,
a manufacturing process which is scalable, and ﬁnally the
Table 10: Key drivers of cationic emulsion technology Novasorb.
(i) Solubilization of large doses of lipophilic drugs and/or large
molecules
(ii) Better penetration through membranes resulting in enhanced
bioavailability
(iii) Potential for drug controlled release
(iv) Stable and can be sterilized
(v) Addition of eﬀective novel routes of administration to
existing marketed drugs
(vi) Expanding markets and indications
(vii) Extending product life cycles
(viii) Generating new opportunities
(ix) Inexpensive to manufacture
animal models and experimental protocols were designed to
carefully screen and select the formulation with the highest
probability of demonstrate clinical safety and eﬃcacy.
The Novasorb success story also proves that authorities,
particularly European authorities, are relatively open to new
delivery approaches and new technologies as long as eﬃcacy
and safety can be conclusively demonstrated according to
well-constructed protocols and studies. Novagali Pharma is
now pursuing the next generation of cationic nanoemul-
sions,whichwillhaveenhancedpharmacokineticsproperties
and new original drug products to expand the reach of
ophthalmic indications. Some other improvements such as
development of new cationic agents will provide continued
support for this promising and eﬀective means of delivering
active molecules.
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